$5.12
2.34%
Downside
Day's Volatility :6.02%
Upside
3.76%
19.92%
Downside
52 Weeks Volatility :47.7%
Upside
34.69%
Period | Collplant Biotechnologies Ltd | Index (Russel 2000) |
---|---|---|
3 Months | -0.19% | 0.0% |
6 Months | 2.2% | 0.0% |
1 Year | -32.59% | 0.0% |
3 Years | -71.28% | -22.3% |
Market Capitalization | 60.4M |
Book Value | $1.81 |
Earnings Per Share (EPS) | -1.53 |
Wall Street Target Price | 12.5 |
Profit Margin | 0.0% |
Operating Margin TTM | -1769.48% |
Return On Assets TTM | -33.77% |
Return On Equity TTM | -61.55% |
Revenue TTM | 689.0K |
Revenue Per Share TTM | 0.06 |
Quarterly Revenue Growth YOY | -97.6% |
Gross Profit TTM | 13.6M |
EBITDA | -17.3M |
Diluted Eps TTM | -1.53 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.25 |
EPS Estimate Next Year | -0.39 |
EPS Estimate Current Quarter | -0.27 |
EPS Estimate Next Quarter | -0.29 |
What analysts predicted
Upside of 144.14%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 4.8M | ↑ 897.75% |
Net Income | -6.2M | ↑ 3.27% |
Net Profit Margin | -130.5% | ↑ 1130.34% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 2.3M | ↓ 51.59% |
Net Income | -14.7M | ↑ 135.19% |
Net Profit Margin | -634.04% | ↓ 503.54% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 6.1M | ↑ 164.75% |
Net Income | -5.8M | ↓ 60.48% |
Net Profit Margin | -94.64% | ↑ 539.4% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 15.6M | ↑ 154.86% |
Net Income | 409.0K | ↓ 107.04% |
Net Profit Margin | 2.61% | ↑ 97.25% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 299.0K | ↓ 98.09% |
Net Income | -16.8M | ↓ 4196.09% |
Net Profit Margin | -5.6K% | ↓ 5605.62% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 11.0M | ↑ 3565.22% |
Net Income | -7.0M | ↓ 58.1% |
Net Profit Margin | -64.05% | ↑ 5538.96% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 433.0K | ↑ 0.0% |
Net Income | -3.9M | ↑ 0.0% |
Net Profit Margin | -903.23% | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 10.2M | ↑ 2251.96% |
Net Income | 5.8M | ↓ 247.33% |
Net Profit Margin | 56.58% | ↑ 959.81% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 43.0K | ↓ 99.58% |
Net Income | -4.4M | ↓ 175.96% |
Net Profit Margin | -10.2K% | ↓ 10235.65% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 299.0K | ↑ 595.35% |
Net Income | -4.7M | ↑ 7.13% |
Net Profit Margin | -1.6K% | ↑ 8610.84% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 249.0K | ↓ 16.72% |
Net Income | -4.2M | ↓ 10.22% |
Net Profit Margin | -1.7K% | ↓ 122.53% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 249.0K | ↑ 0.0% |
Net Income | -4.2M | ↑ 0.0% |
Net Profit Margin | -1.7K% | ↑ 0.0% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 9.0M | ↑ 12.15% |
Total Liabilities | 4.3M | ↓ 21.37% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 10.8M | ↑ 18.81% |
Total Liabilities | 6.7M | ↑ 55.35% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 10.8M | ↑ 0.83% |
Total Liabilities | 6.4M | ↓ 4.5% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 51.2M | ↑ 372.5% |
Total Liabilities | 6.1M | ↓ 4.1% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 37.8M | ↓ 26.27% |
Total Liabilities | 5.5M | ↓ 10.09% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 34.1M | ↓ 9.64% |
Total Liabilities | 5.8M | ↑ 5.45% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 35.8M | ↑ 0.0% |
Total Liabilities | 5.9M | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 41.6M | ↑ 16.25% |
Total Liabilities | 5.5M | ↓ 5.78% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 37.6M | ↓ 9.65% |
Total Liabilities | 5.2M | ↓ 6.69% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 34.1M | ↓ 9.14% |
Total Liabilities | 5.8M | ↑ 12.13% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 26.6M | ↓ 22.15% |
Total Liabilities | 5.8M | ↑ 0.88% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 26.6M | ↑ 0.0% |
Total Liabilities | 5.8M | ↑ 0.0% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -1.2M | ↓ 75.93% |
Investing Cash Flow | -832.0K | ↑ 555.12% |
Financing Cash Flow | 2.6M | ↓ 71.76% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -5.7M | ↑ 360.42% |
Investing Cash Flow | -1.5M | ↑ 75.6% |
Financing Cash Flow | 5.4M | ↑ 105.5% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -4.5M | ↓ 21.95% |
Investing Cash Flow | -519.0K | ↓ 64.48% |
Financing Cash Flow | 4.5M | ↓ 17.47% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.5M | ↓ 156.19% |
Investing Cash Flow | -31.6M | ↑ 5980.15% |
Financing Cash Flow | 38.8M | ↑ 768.09% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.5M | ↑ 0.0% |
Investing Cash Flow | -396.0K | ↑ 30.26% |
Financing Cash Flow | 803.0K | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.7M | ↑ 8.52% |
Investing Cash Flow | -396.0K | ↑ 0.0% |
Financing Cash Flow | 89.0K | ↓ 88.92% |
Sell
Neutral
Buy
Collplant Biotechnologies Ltd is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Collplant Biotechnologies Ltd | 10.82% | 2.2% | -32.59% | -71.28% | 30.95% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Collplant Biotechnologies Ltd | NA | NA | NA | -1.25 | -0.62 | -0.34 | NA | 1.81 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Collplant Biotechnologies Ltd | Buy | $60.4M | 30.95% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Collplant Biotechnologies Ltd
Revenue is down for the last 3 quarters, 299.0K → 249.0K (in $), with an average decrease of 8.4% per quarter
Netprofit is up for the last 3 quarters, -4.68M → -4.21M (in $), with an average increase of 5.7% per quarter
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 69.7%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 140.5%
Parallel Advisors, LLC
collplant is a regenerative medicine company focused on 3d bioprinting of tissues and organs, and on developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets. our products are based on our rhcollagen (recombinant human collagen) that is produced with collplant’s proprietary plant based genetic engineering technology. our products address indications for diverse fields of organ and tissue repair, and are ushering in a new era in regenerative medicine. our flagship rhcollagen bioink product line is ideal for 3d bioprinting of tissues and organs, and our unique vergenix line of rhcollagen products includes a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote a rapid optimal healing of acute and chronic wounds. collplant is a public company listed on the tel aviv stock exchange and on nasdaq (clgn).
Organization | Collplant Biotechnologies Ltd |
Employees | 75 |
CEO | Mr. Yehiel Tal |
Industry | Health Technology |
A Spac I Acquisition Corp
$5.12
-2.85%
Keyarch Acquisition Corp
$5.12
-2.85%
Connexa Sports Technologies Inc
$5.12
-2.85%
Us Value Etf
$5.12
-2.85%
First Wave Biopharma Inc
$5.12
-2.85%
Global X Msci Next Emerging
$5.12
-2.85%
Fat Projects Acquisition Corp
$5.12
-2.85%
Capital Link Global Fintech
$5.12
-2.85%
Applied Uv Inc
$5.12
-2.85%